Charles Schwab Investment Management Inc Avidity Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,028,931 shares of RNA stock, worth $35.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,028,931
Previous 990,182
3.91%
Holding current value
$35.3 Million
Previous $45.5 Million
34.21%
% of portfolio
0.01%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding RNA
# of Institutions
250Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$365 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$317 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$296 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$279 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$241 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.79B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...